@article {Martinez-Portilla2020.05.31.20107276, author = {Raigam J. Martinez-Portilla and Alexandros Sotiriadis and Johnatan Torres-Torres and Chatzakis Christos and Ameth Hawkins-Villarreal and Jose R. Villafan-Bernal and Rodolfo A. Gurrola-Ochoa and Francesc Figueras}, title = {Risk factors for mortality in pregnant women with SARS-CoV-2 infection}, elocation-id = {2020.05.31.20107276}, year = {2020}, doi = {10.1101/2020.05.31.20107276}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Since the first case of pneumonia was described, SARS-CoV-2 infection (coronavirus disease [COVID]-19) rapidly spread worldwide With 94,288 infections and more than 10,000 deaths, Mexico is the third Latin-American country in number of confirmed cases and second in mortality1. A major risk factor for adverse outcome in COVID-19 infection is the presence of advance age, co-morbidities including diabetes, hypertension and obesity among other non-communicable diseases2. Epidemiological data from high-prevalence countries reveal that compared to men, women are less likely to die or to require hospital admission to intensive care. This may suggest that pregnant women are not more susceptible to infection or to experience serious complications. However, whether the presence of co-morbidities or advanced maternal age confers a higher risk of adverse outcome in pregnant women with COVID-19 is unknown3.In this research letter, we aimed at evaluating the risk factor associated with maternal mortality secondary to COVID-19 infection in a middle-income country.Advanced maternal age is linked to an increased risk of mortality, while diabetes is the most important risk factor for maternal death. This is partly explained by an increasing incidence of non-communicable diseases in women of advanced age which is a common feature in most countries4. In the last decades, low- and middle-income countries have experienced accelerated socio-cultural changes associated with its incorporation into the international economic community, which have increased the number of obese and diabetic population, including pregnant women5. This has caused an increased risk for complications and fatality among COVID-19 positive population2,3. Thus, policies for reducing obesity and diabetes in low- and middle-income countries are most needed to reduce the mortality of COVID-19 in pregnant women.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational study using freely available data. There is no need for trial registrationFunding StatementThere were no fundings for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the General Hospital{\textquoteright}s Ethics committee No. DI/20/112/04/24All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available by correspondence by contacting the corresponding author}, URL = {https://www.medrxiv.org/content/early/2020/06/02/2020.05.31.20107276}, eprint = {https://www.medrxiv.org/content/early/2020/06/02/2020.05.31.20107276.full.pdf}, journal = {medRxiv} }